It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.

A recent report from MarketsAndMarkets projected that the global gastric cancer market accounted for USD 3.01 billion in 2023 and is expected to reach USD 18.43 billion by 2034 with a CAGR of 17.92% ...

Broad enrollment criteria appear to have scuttled the trial, which was designed to test whether ctDNA could identify patients ...

Manufacturing practices are evolving to advance antibody drug conjugates (ADCs) for cancer treatment through a targeted approach.

Independent Analysis of Annual Sales Forecasts by Distribution Channel (Retail Pharmacies, Online Pharmacies, Other ...

The global opioid use disorder treatment market is poised for significant growth, with an expected market size of USD 3.07 ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

GSK (GSK) announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended expanding the approval of Jemperli in combination with chemotherapy ...

GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) ...

GSK’s B7-H3-targeted ADC, GSK’227, receives EMA PRIME designation in relapsed extensive-stage small-cell lung cancer: London, UK Tuesday, December 17, 2024, 12:00 Hrs [IST] GS ...

US FDA grants breakthrough therapy designation to GSK’s Jemperli for locally advanced dMMR/MSI-H rectal cancer: London, UK Tuesday, December 17, 2024, 09:00 Hrs [IST] GSK plc an ...

GSK is hosting the third annual RespiVerse Meeting in Bangkok, Thailand. The event brings together renowned international ...